VERESCA PRECISION ONCOLOGY
US | Onconostic Technologies, Inc.
EU | 3N Diagnostics Ltd.
®
DEVELOPING TREATMENT PLANS WITH PERSONALIZED BLUEPRINTS PREDICTING DISEASE PROGRESSION
FOXC1 PROMETASTATIC CANCER
Aggressive, invasive tumors with high metastatic propensity.
A SINGLE IHC BIOMARKER HIGHLY SPECIFIC FOR BLBC (IN ER+, HER2+, TNBC)
FOXC1 Industry Leader having discovered the oncogenic properties of FOXC1 in 2010. Demonstrated single gene's mRNA and protein over expression was substantially equivalent to BLBC multi-gene analysis on multiple platforms under multivariate analysis.
GUIDES CLINICIAN ON THE APPROPRIATE REGIMEN FOR NACT
FOXC1 is an independent predictor under multivariate analysis of pathological complete response (pCR) in neoadjuvant chemotherapy (NACT).
FOXC1 positive TNBC patients have significantly higher pCR rates than in FOXC1 negative TNBC patients (34.44% vs. 3.13%, p < 0.001) [245]
IDENTIFIES PATIENTS WHO HAVE HIGH RECURRENCE RISKS WITH ANTHRACYCLINE
FOXC1 identifies patients with high risk of local recurrence and distant metastasis with anthracycline (doxyrubicin) with worse DFS (HR 2.62, 95% CI 1.05-6.50, P = 0.038)I 1.05-6.50, P = 0.038)
SELECT PATIENTS WHO MAY BENEFIT FROM TAXANE PLUS PLATINUM (TP) REGIME
FOXC1 mRNA expression has been retrospectively validated as a predictor of pCR in TNBC patients treated with taxane plus platinum (TP) regimens. High FOXC1 expression was associated with higher pCR rates in multiple cohorts, with rates of 43.48%, 47.89%, and 52.73%
IDENTIFIES BLBC IN BRCA1 AND BRCA2 TUMORS AND SENSITIVITY TO PARP INHIBITORS
Independent predictor identifying individuals who benefit (DRFS, DFS, OS) from continued capecitabine therapy after (neo) adjuvant chemotherapy in early TNBC
INDEPENDENT PREDICTOR OF NACT pCR IN AR+ TNBC
FOXC1 can be found in 51% of AR+ TNBC. 28% (7/25) of FOXC1 +, AR+ 35.7% (45/126)FOXC1+, AR neg tumors acheved pCR.
​
Non-pCR AR+ (42/49) have high PI3K|AKT|mTOR mutations
​